Clinical Trial

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined with nab-paclitaxel and cisplatin preoperatively and adebrelimab (SHR-1316) single-agent adjuvant therapy postoperatively, to observe the efficacy and safety of this treatment modality, and to provide clinical evidence for the use of PD-L1 monoclonal antibody in perioperative treatment of esophageal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT06869213
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Esophageal Cancer (EsC)
Enrollment 30 participants
Start Date 2025-03-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02